On Jan. 20, the Biden administration named Dr. Janet Woodcock acting commissioner of the U.S. Food and Drug Administration (FDA).

As The New York Times reported over the weekend, Woodcock is “one of two leading contenders” to lead the agency, but she faces “strong opposition.”

Among those opposing Woodcock’s appointment as FDA commissioner is as  a coalition of nonprofit advocacy groups who argue that Woodcock’s “inadequate” oversight of the FDA during the opioid crisis should disqualify her. In a letter to officials at the Department of Health and Human Services, the coalition wrote:

“In its opioid decision-making, Dr. Woodcock, and the division she supervised, consistently put the interests of opioid manufacturers ahead of public health, often overruling its own scientific advisors and ignoring the pleas of public health groups, state Attorneys General, and outraged victims of the opioid crisis.”

(See link for article)